甘李药业股份有限公司（"公司"）第五届监事会第二次会议于 2025 年 7 月 15 日以电子邮件方式发出会议通知和会议材料，2025 年 7 月 21 日在公司五 层会议室以现场会议的形式召开。本次会议由监事会主席张立主持。应出席监事 3 名，实际出席监事 3 名。本次会议的召开符合《公司法》和《公司章程》的有 关规定，会议决议合法有效。 证券代码：603087 证券简称：甘李药业 公告编号：2025-052 甘李药业股份有限公司 第五届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 公司关于继续使用闲置募集资金进行现金管理的公告》（公告编号：2025-053）。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： （一）审议通过了《关于继续使用闲置募集资金进行现金管理的议案》 监事会同意公司在保障资金安全及确保不影响募集资金投资项目建设和使 用计划的前提下，继续使用不超过人民币 2.5 亿元的暂时闲置募 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-051 甘李药业股份有限公司 第五届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 甘李药业股份有限公司（"公司"）第五届董事会第二次会议于 2025 年 7 月 15 日以电子邮件方式发出会议通知和会议材料，2025 年 7 月 21 日在公司五 层会议室以现场结合通讯方式召开。本次会议由董事长陈伟先生主持。应出席董 事 9 名，实际出席董事 9 名，公司监事及高级管理人员列席本次会议。本次会议 的召开符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 董事会同意公司在保障资金安全及确保不影响募集资金投资项目建设和使 用计划的前提下，继续使用不超过人民币 2.5 亿元的暂时闲置募集资金适时购买 安全性高、流动性好、满足保本要求的投资产品（包括协定性存款、结构性存款、 定期存款、大额存单、收益凭证等），且该等投资产品不得用于质押，不用于以 证券投资为目的的投资行为。同时不影响募集资金投资计划正常进行。期限自 ...

从上证健康产业指数持仓样本的行业来看，医药卫生占比39.55%、主要消费占比29.68%、工业占比 24.70%、公用事业占比6.07%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本比例一般不超过20%。权重因子随样本定期调整而调整，调整时间与指数样本 定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临 时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。 金融界7月21日消息，上证指数高开高走，上证健康产业指数 (上证健康，H50044)报1143.60点。 从指数持仓来看，上证健康产业指数十大权重分别为：上海洗霸（3.12%）、药明康德（2.5%）、生物 股份（2.38%）、中牧股份（2.2%）、道通科技（2.18%）、福龙马（2.14%）、恒瑞医药（2.12%）、 惠泰医疗（2.11%）、甘李药业（2.06%）、海南橡胶（2.05%）。 数据统计显示，上证健康产业指数近一个月上涨4.93%，近三个月上涨8.76%，年至今上涨7.27 ...

Summary of Conference Call Notes Industry or Company Involved - The discussion primarily revolves around the pharmaceutical industry, particularly focusing on the implications of U.S. drug pricing policies and U.S.-China trade negotiations on Chinese pharmaceutical companies and their market opportunities. Core Points and Arguments 1. **Positive Impact of U.S.-China Negotiations on Pharmaceuticals** The recent U.S.-China negotiations are viewed as a significant positive for the pharmaceutical sector, alleviating previous concerns regarding trade impacts on drug pricing and exports of innovative drugs and raw materials [1] 2. **U.S. Drug Pricing Policy Changes** Trump's announcement of an executive order to reduce prescription drug prices by 30% to 80% is highlighted. The U.S. drug pricing system, characterized by high list prices, is under scrutiny, with the potential for significant price reductions impacting the market [2][3] 3. **Global Drug Pricing Context** U.S. drug prices are noted to be among the highest globally, particularly for innovative drugs, which are approximately 300% higher than prices in countries like Japan and Germany. This pricing structure encourages innovation but also raises concerns about affordability [3] 4. **Encouragement of Competition** The U.S. policy aims to accelerate competition among high-priced drugs, encouraging the entry of biosimilars and generic drugs, which could benefit Chinese pharmaceutical companies that can offer lower-cost alternatives [4][6] 5. **Opportunities for Chinese Pharmaceutical Companies** The reduction in U.S. drug prices is expected to create opportunities for Chinese companies, particularly in the fast-follow and biosimilar segments, as they can provide high-quality, cost-effective alternatives [6][8] 6. **Long-term Trends Favoring Chinese Innovation** The inefficiencies in innovation among multinational pharmaceutical companies may lead to increased reliance on Chinese innovation and manufacturing capabilities, especially if U.S. companies face cost pressures [7][8] 7. **Market Dynamics and Export Opportunities** The easing of trade tensions is anticipated to enhance the macroeconomic environment in China, leading to improved domestic demand and potential export opportunities for medical devices and raw materials [10][9] 8. **Impact of Drug Price Reductions on Market Dynamics** The anticipated drug price reductions in the U.S. are not expected to significantly diminish the addressable market for Chinese companies, as their market share in the U.S. remains relatively small [11][12] 9. **Long-term Supply Chain Considerations** U.S. concerns regarding supply chain security may lead to a push for domestic manufacturing, which could have long-term implications for Chinese companies seeking to penetrate the U.S. market [14][15] 10. **Investment Recommendations** The call suggests focusing on three categories of companies: innovative leaders, those with strong business development (BD) expectations, and upstream suppliers with global advantages, as the market enters a new growth cycle [16][18] Other Important but Possibly Overlooked Content 1. **Sector-Specific Insights** The discussion includes insights into specific companies and their competitive advantages, such as the potential for certain drugs to achieve significant market penetration despite pricing pressures [31][33] 2. **Emerging Trends in Medical Devices** The call also touches on the medical device sector, emphasizing the importance of high-end equipment and the potential for growth in home healthcare products, which may offer higher profit margins compared to domestic markets [25][26] 3. **Long-term Growth Projections** There is an optimistic outlook for the pharmaceutical sector, with expectations of a gradual recovery in demand and performance improvements in the coming years, driven by policy support and market dynamics [29][40] 4. **Focus on Innovation and R&D** The emphasis on innovation and the need for companies to adapt to changing market conditions is reiterated, highlighting the importance of R&D in maintaining competitive advantages [19][20] 5. **Market Sentiment and Future Outlook** The overall sentiment is cautiously optimistic, with a belief that the current market conditions present opportunities for growth and investment in the pharmaceutical and medical device sectors [46][47]

Core Viewpoint - The performance forecasts of A-share listed pharmaceutical companies for the first half of 2025 reveal a mixed outlook, with some companies showing significant profit growth while others are expected to incur losses, highlighting both opportunities and challenges in the sector [1][5]. Group 1: Performance Highlights - As of July 15, 97 pharmaceutical stocks have disclosed their performance forecasts, with 20 companies expecting a net profit increase of over 100% and 53 companies anticipating year-on-year profit growth [1]. - WuXi AppTec (药明康德) is projected to have the highest net profit among the disclosed forecasts, expecting approximately 8.561 billion yuan, a year-on-year increase of 101.92% [4]. - Asia-Pacific Pharmaceutical (亚太药业) is noted as the "profit growth king," with an expected net profit increase of 1726.42% to 1909.06%, primarily due to the sale of a subsidiary [3]. Group 2: Loss Forecasts - A total of 42 pharmaceutical stocks are expected to report losses in the first half of 2025, with notable companies like Da An Gene (达安基因) and Hainan Haiyao (海南海药) projecting significant losses [5][7]. - Da An Gene anticipates a loss of 140 million to 200 million yuan, although this represents a reduction in losses compared to the previous year [5]. - 18 companies, including Wantai Biological Pharmacy (万泰生物) and Lianhuan Pharmaceutical (联环药业), are expected to report their first-ever half-year losses since listing [7][9]. Group 3: Market Dynamics - Wantai Biological attributes its expected loss to industry policy adjustments and market competition affecting its vaccine sales, while also banking on the launch of its domestically developed nine-valent HPV vaccine to improve future performance [7][8]. - Lianhuan Pharmaceutical's loss is linked to multiple factors, including national drug procurement policies and increased international market competition, which have pressured its gross margins [9].

证券代码：603087 证券简称：甘李药业 公告编号：2025-050 甘李药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次委托理财概况 投资种类：银行理财产品 投资金额：2 亿元 履行的审议程序：甘李药业股份有限公司（以下简称"公司"）于 2024 年 7 月 25 日召开的第四届董事会第二十一次会议及第四届监事会第二 十次会议审议通过了《关于继续使用闲置募集资金进行现金管理的议 案》，同意在保障资金安全及确保不影响募集资金投资项目建设和使 用计划的前提下，继续使用不超过人民币 2.5 亿元的暂时闲置募集资 金适时购买安全性高、流动性好、满足保本要求的投资产品（包括协 定性存款、结构性存款、定期存款、大额存单、收益凭证等），且该 等投资产品不得用于质押，不用于以证券投资为目的的投资行为。同 时不影响募集资金投资计划正常进行。期限自董事会审议通过之日起 不超过 12 个月。上述期限及额度范围内，资金可循环滚动使用。具体 内容详见公司在上海证券 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-050 甘李药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 投资种类：银行理财产品 一、本次委托理财概况 （一）委托理财目的 为提高公司资金使用效率，在不影响募集资金投资项目建设的前提下，对闲 置募集资金进行现金管理，增加公司的收益，为公司及股东获取更多回报。 （二）投资金额 公司本次进行委托理财的投资金额为 2 亿元。 公司招股说明书披露的首次公开发行股票募集资金投资项目及募集资金使 用计划如下： | 序 | 募集资金投资项目 | 项目投资总额 | | 拟使用募集资金 | | | --- | --- | --- | --- | --- | --- | | 号 | | （万元） | | （万元） | | | | | 合计 | | 258,209.53 | 244,113.45 | | | 截至 2024 年 | 12 月 | 31 | 日,公司对募集资金项目累计投入 | 2,080,960,906.26 | 元，募集资金账户产 ...

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug companies [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.82%, outperforming the CSI 300 index (0.82%) and the Wind All A index (1.71%). The market is currently focused on the expectations surrounding semi-annual reports and business development (BD) activities [8][9]. - The launch of the 2025 National Basic Medical Insurance and Commercial Health Insurance innovative drug directory is a significant development. This directory will include high-innovation drugs that provide substantial clinical value and patient benefits, which are not covered by basic medical insurance but recommended for commercial health insurance [3][13]. - The report highlights the importance of the commercial health insurance sector in the payment for innovative drugs, suggesting that the accessibility of high-priced innovative drugs is expected to improve, particularly in the areas of cell and gene therapy [3][13]. Market Weekly Review - The medical research outsourcing sector led the gains with a 9.29% increase, primarily driven by WuXi AppTec's positive semi-annual report announcement. Conversely, offline pharmacies and other biological products experienced declines of -1.29% and -1.55%, respectively [8][9]. - Notable stock performances included Frontier Biotech-U (41.4%), Mediso (38.9%), and Lianhuan Pharmaceutical (38.6%) leading the gains, while ST Unimed (-18.5%), Shenzhou Cell-U (-13.4%), and Shutai Shen (-11.6%) faced significant losses [11][12]. Industry News and Key Company Announcements - The report outlines several key industry events, including the approval of innovative drugs and strategic partnerships among major pharmaceutical companies, which are expected to enhance their market positions and product offerings [13][16][17]. - The report also mentions significant financial forecasts from various companies, indicating strong growth potential in the sector, with some companies projecting net profit increases of over 100% year-on-year [17][18].

甘李药业（603087.SH）交出了一份不错的上半年成绩单。根据业绩预告，这家公司2025年上半年预计 归母净利润达6.0～6.4亿元，同比增长超100%，接近2024年全年水平。 公告发布次日，甘李药业盘中一度上涨2.11%。对比2022年集采带来的利润滑坡，这一"翻番式修复"无 疑成为市场情绪转折点。 但支撑甘李药业反转的，不只是财务指标，更是一连串战略动作：国内通过续约集采提价锁量、降本增 效重塑模式；海外则以巴西PDP为代表，开辟技术出海通道。 那么，甘李药业新增长点能否持续兑现业绩？集采压力是否真正摆脱？ 量价循环重新确立 2021年底，国家医保局启动首轮胰岛素带量采购，甘李药业六款产品中标，核心产品甘精胰岛素报价 48.71元/支，降幅63%。虽然获得了100%基础量，但公司2022年营收同比下降52.6%至17.12亿元，净利 润转为亏损4.40亿元，毛利率从84.6%骤降至63.1%。公司同时承担约3.1亿元库存补差，遭遇上市以来 最严重的利润断崖。 集采阵痛倒逼甘李药业调整商业模式。2022年底公司对营销网络动刀，将原有约1200人的学术推广队伍 裁撤37%，销售策略从高成本医院转向数字化学 ...

Group 1 - Jichuan Pharmaceutical's "Children's Constipation Granules" has received a registration application acceptance notice, marking it as the first innovative traditional Chinese medicine specifically for treating pediatric constipation [1] - The product is expected to be the first Class 1 pediatric-specific drug for constipation following the release of the clinical research guidelines in 2024 [1] Group 2 - Innovent Biologics' drug Daberat® has become the first KRAS G12C inhibitor approved in Macau, providing a new targeted therapy for patients with advanced non-small cell lung cancer [2] - In a Phase II clinical trial, Daberat® demonstrated an objective response rate (ORR) of 49.1%, a median progression-free survival (PFS) of 9.7 months, and a 12-month overall survival (OS) rate of 54.4% [2] Group 3 - Sinovac Biotech's special shareholders meeting approved the election of 10 new directors proposed by SAIF Partners, who committed to support the company's dividend distribution plan [3] - The new board members aim to work closely with management to restore trading of the company's common stock and enhance long-term shareholder value [3] Group 4 - Ganli Pharmaceutical expects a net profit increase of 100.73% to 114.12% for the first half of 2025, with projected profits between 600 million to 640 million yuan [4] - The company achieved market share expansion through two rounds of insulin procurement, with a significant 32.6% increase in agreement volume during the 2024 procurement [4] Group 5 - Ascentage Pharma's new Bcl-2 inhibitor, Lisangtuo® (APG-2575), has been conditionally approved for marketing in China, becoming the first Bcl-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma [5] - This marks Ascentage Pharma's second innovative drug to be approved and enter the commercialization stage [5] Group 6 - United Biomedical's UBT37034 injection has received FDA approval for clinical trials, showing significant weight reduction effects when combined with GLP-1 analogs in preclinical studies [6] - The combination therapy demonstrated superior weight loss effects compared to other investigational drugs [6]